Back to User profile » Dr Yiran Huang
Paper published by Dr Yiran Huang:
Original Research
![Noteworthy comment: The paper is important because it is the first phase III trial after the registrative trial investigating the role of axitinib in Asian population.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D
OncoTargets and Therapy 2015, 8:1363-1373
Published Date: 8 June 2015